Resolving the Negative Data Publication Dilemma in Translational Stroke Research

Translational Stroke Research

Volumn 2, Issue 1, 2011, Pages 1-6

  Lapchak, Paul A ^a   Zhang, John H ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; DESMOTEPLASE; DIHYDROPYRIDINE; DISUFENTON SODIUM; DOCOSAHEXAENOIC ACID; FIBRINOLYTIC AGENT; HIGH MOBILITY GROUP B1 PROTEIN; NIMODIPINE; TAURINE; UROKINASE;

BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FIBRINOLYTIC THERAPY; HEART STROKE VOLUME; HUMAN; IN VITRO STUDY; MEDICAL SOCIETY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PUBLICATION; RANKIN SCALE;

EID: 79951508122     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-010-0057-x     Document Type: Editorial

References (45)

1. Turner R, Jickling G, Sharp F. Are underlying assumptions of current animal models of human stroke correct: From STAIRS to high hurdles? Transl Stroke Res. 2011; 2(1).
2. Ning M, Lo EH. Opportunities and challenges in omics. Transl Stroke Res. 2010; 1(4): 233-7.
3. Jickling GC, Zhan X, Ander BP, Turner RJ, Stamova B, Xu H, et al. Genome response to tissue plasminogen activator in experimental ischemic stroke. BMC Genomics. 2010; 11: 254.
4. Liu DZ, Tian Y, Ander BP, Xu H, Stamova BS, Zhan X, et al. Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J Cereb Blood Flow Metab. 2010; 30(1): 92-101.
5. Lapchak PA, Schubert DR, Maher PA. Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. J Neurochem. 2011; 116(1): 122-131.
6. Lapchak PA, KcKim, JM. CeeTox™ analysis of CNB-001 a novel curcumin-based neurotrophic/neuroprotective lead compound to treat stroke: Comparison with NXY-059 and Radicut. Transl Stroke Res. 2011; 2(1).
7. Maher P, Salgado KF, Zivin JA, Lapchak PA. A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res. 2007; 1173: 117-25.
8. Adeoye O, Clark JF, Khatri P, Wagner KR, Zuccarello M, Pyne-Geithman GJ. Do current animal models of intracerebral hemorrhage mirror the human pathology? Transl Stroke Res. 2011; 2(1).
9. Lapchak PA. Translational stroke research using a rabbit embolic stroke model: A correlative analysis hypothesis for novel therapy development. Transl Stroke Res. 2010; 1(2): 96-107 [Perspective Review].
10. Brown AT, Skinner RD, Flores R, Hennings L, Borrelli MJ, Lowery J, et al. Stroke location and brain function in an embolic rabbit stroke model. J Vasc Interv Radiol. 2010; 21(6): 903-9.
11. Sugawara T, Ayer R, Jadhav V, Zhang JH. A new grading system evaluating bleeding scale in filament perforation subarachnoid hemorrhage rat model. J Neurosci Methods. 2008; 167(2): 327-34.
12. Hartman R, Lekic T, Rojas H, Tang J, Zhang JH. Assessing functional outcomes following intracerebral hemorrhage in rats. Brain Res. 2009; 1280: 148-57.
13. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: Mechanisms in search of treatments. Neuron. 2010; 67(2): 181-98.
14. Arai K, Jin G, Navaratna D, Lo EH. Brain angiogenesis in developmental and pathological processes: Neurovascular injury and angiogenic recovery after stroke. FEBS J. 2009; 276(17): 4644-52.
15. Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology. 2009; 72(15): 1310-15.
16. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007; 38(11): 3055-62.
17. Mandava P, Kent TA. A method to determine stroke trial success using multidimensional pooled control functions. Stroke. 2009; 40(5): 1803-10.
18. Kellner CP, Connolly Jr ES. Neuroprotective strategies for intracerebral hemorrhage: Trials and translation. Stroke. 2010; 41(10 Suppl): S99-102.
19. Dirnagl U, Lauritzen M. Fighting publication bias: Introducing the Negative Results section. J Cereb Blood Flow Metab. 2010; 30(7): 1263-4.
20. Hebert RS, Wright SM, Dittus RS, Elasy TA. Prominent medical journals often provide insufficient information to assess the validity of studies with negative results. J Negat Results Biomed. 2002; 1: 1.
21. Probst JC. Prisoners' dilemma: The importance of negative results. Fam Med. 2006; 38(10): 742-3.
22. Littner Y, Mimouni FB, Dollberg S, Mandel D. Negative results and impact factor: A lesson from neonatology. Arch Pediatr Adolesc Med. 2005; 159(11): 1036-7.
23. Fanelli D. Do pressures to publish increase scientists' bias? An empirical support from US States data. PLoS ONE. 2010; 5(4): e10271.
24. NINDS. Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-PA stroke study group. N Engl J Med. 1995; 333(24): 1581-7.
25. Belayev L, Khoutorova L, Atkins KD, Eady TN, Hong S, Lu Y, Obenaus A, Bazan NG. Docosahexaenoic acid therapy of experimental ischemic stroke. Transl Stroke Res. 2011; 2(1).
26. Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2004; 185(1): 154-9.
27. Guan W, Zhao G, Xu C. A combined treatment with taurine and intra-arterial thrombolysis in an embolic model of stroke in rats: Increased neuroprotective efficacy and extended therapeutic time window. Transl Stroke Res. 2011; 2(1).
28. Hoffmann A, Bredno J, Wendland M, Derugin N, Ohara P, Wintermark M. High and Low molecular weight fluorescein Isothiocyanate (FITC)-dextrans to assess blood-brain barrier disruption: Technical considerations. Transl Stroke Res. 2011; 2(1).
29. Woitzik J, Hohenstein A, Hecht N, Juettler E, Schilling L. Short period of early reperfusion aggravates blood-brain barrier dysfunction during permanent focal ischemia in rats. Transl Stroke Res. 2011; 2(1).
30. Dorhout Mees SM RG, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007; 3(CD000277).
31. Murakami K, Koide M, Dumont TM, Russell SR, Tranmer BI, Wellman GC. Subarachnoid hemorrhage induces gliosis and increased expression of the pro-inflammatory cytokine high mobility group box 1 protein. Transl Stroke Res. 2011; 2(1).
32. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13): 1317-29.
33. Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T, et al. Underlying structure of the national institutes of health stroke scale: Results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke. 1999; 30(11): 2347-54.
34. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007; 357(6): 562-71.
35. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009; 8(2): 141-50.
36. Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof B, Devlin T, et al. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke. 2009; 40(4): 1359-64.
37. Lampl Y, Zivin JA, Fisher M, Lew R, Welin L, Dahlof B, et al. Infrared laser therapy for ischemic stroke: A new treatment strategy: Results of the NeuroThera effectiveness and safety trial-1 (NEST-1). Stroke. 2007; 38(6): 1843-9.
38. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006; 354(6): 588-600.
39. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006; 37(5): 1227-31.
40. Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR. Effects of NXY-059 in experimental stroke: An individual animal meta-analysis. Br J Pharmacol. 2009; 157(7): 1157-71.
41. DIAS-4. http://clinicaltrials. gov/ct2/show/NCT00856661. 2010.
42. Lapchak PA. Taking a light approach to treating acute ischemic stroke patients: Transcranial near-infrared laser therapy translational science. Ann Med. 2010; 42(8): 576-86.
43. NEST-3. http://clinicaltrials. gov/ct2/show/NCT01120301. 2010.
44. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: Is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010; 11(10): 1753-63.
45. MCI-186. http://clinicaltrials. gov/ct2/show/NCT00821821. 2010.